WO2023073013 - LRRK2 INHIBITORS
National phase entry:
Publication Number
WO/2023/073013
Publication Date
04.05.2023
International Application No.
PCT/EP2022/079927
International Filing Date
26.10.2022
Title **
[English]
LRRK2 INHIBITORS
[French]
INHIBITEURS DE LRRK2
Applicants **
H. LUNDBECK A/S
Inventors
JENSEN, Thomas
JESSING, Mikkel
YU, Wanwan
DIAZ, David Rodriguez
NIELSEN, Jacob
JONES, Christopher Richard
ANDERSEN, Thomas
JACOBSEN, Mikkel Fog
Priority Data
21204970.4
27.10.2021
EP
22201380.7
13.10.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3904 | |
| EPO | Filing, Examination, Granting | 18824 | |
| Japan | Filing, Examination, Granting | 2431 | |
| South Korea | Filing, Examination, Granting | 2663 | |
| USA | Filing, Examination, Granting | 8090 |
Total:
35,912
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is directed to compounds of formula I. The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.[French]
La présente invention concerne des composés de formule I. Les composés sont considérés utiles pour le traitement de maladies associées à LRRK2 telles que la maladie de Parkinson.